Boehringer Ingelheim GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Scope
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – GlobalData’s summarization of the company’s business strategy.
- SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
Highlights
Boehringer Ingelheim GmbH (Boehringer), a subsidiary of C. H. Boehringer Sohn AG & Co KG is a pharmaceutical company, which carries out research, development, manufacture and sale of pharmaceuticals. The company offers a wide range of products including prescription medicines, consumer health care products, animal health care products and biopharmaceuticals. Its products are used in the treatment of central nervous system disorders, respiratory diseases, cardiovascular diseases, metabolic disorders, cancer, urological and viral conditions, among others. The company focuses on the research, development, manufacture and marketing of new drugs of therapeutic value for human and veterinary medicine. Boehringer operates globally through affiliates and is headquartered in Ingelheim am Rhein, Rheinland-Pfalz, Germany.
Boehringer Ingelheim GmbH Key Recent Developments
Mar 13,2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim
Mar 02,2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million
Jan 23,2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting
Nov 30,2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment
Oct 18,2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers
Reasons to Buy
- Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
- Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
- Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 - About the Company 6
Boehringer Ingelheim GmbH - Key Facts 6
Boehringer Ingelheim GmbH - Key Employees 7
Boehringer Ingelheim GmbH - Key Employee Biographies 8
Boehringer Ingelheim GmbH - Major Products and Services 9
Boehringer Ingelheim GmbH - Pharmaceutical Pipeline Products Data 11
Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area 11
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase 12
Boehringer Ingelheim GmbH - History 13
Boehringer Ingelheim GmbH - Company Statement 24
Boehringer Ingelheim GmbH - Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Section 2 – Company Analysis 26
Boehringer Ingelheim GmbH - Business Description 26
Boehringer Ingelheim GmbH - Corporate Strategy 27
Boehringer Ingelheim GmbH - SWOT Analysis 28
SWOT Analysis - Overview 28
Boehringer Ingelheim GmbH - Strengths 28
Boehringer Ingelheim GmbH - Weaknesses 29
Boehringer Ingelheim GmbH - Opportunities 30
Boehringer Ingelheim GmbH - Threats 31
Boehringer Ingelheim GmbH - Key Competitors 32
Section 3 – Company’s Lifesciences Financial Deals and Alliances 33
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Boehringer Ingelheim GmbH, Recent Deals Summary 35
Section 4 – Company’s Recent Developments 36
Mar 13, 2017: FORMA Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim 36
Mar 02, 2017: Boehringer Ingelheim sponsors the new building of the Research Institute of Molecular Pathology in Vienna with EUR 52 million 37
Jan 23, 2017: Inovalon Announces Agreement With Boehringer Ingelheim to Support Outcome-Based Contracting 38
Nov 30, 2016: Boehringer Ingelheim Selects ACD/Labs for International Deployment 39
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 40
Aug 03, 2016: Boehringer Ingelheim: Growth in all core businesses 42
Jul 20, 2016: The European Stroke Organisation and Boehringer Ingelheim launch the “Angels Initiative”, a unique healthcare initiative to improve acute stroke care across Europe 44
Jul 04, 2016: Gaia Novarino wins Boehringer Ingelheim’s FENS Award 2016 for Exceptional Research in Neuroscience 45
Jun 10, 2016: Simone Menne – new Member of the Board of Managing Directors of Boehringer Ingelheim/Responsible for Corporate Board Division Finance 46
May 23, 2016: Boehringer Ingelheim and BioMed X start new project to explore and develop unprecedented new treatment approaches for psychiatric diseases applying crowdsourcing 47
Section 5 – Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
List of Tables
Boehringer Ingelheim GmbH, Key Facts 6
Boehringer Ingelheim GmbH, Key Employees 7
Boehringer Ingelheim GmbH, Key Employee Biographies 8
Boehringer Ingelheim GmbH, Major Products and Services 9
Boehringer Ingelheim GmbH, Number of Pipeline Products by Therapy Area 11
Boehringer Ingelheim GmbH, Number of Pipeline Products by Development Stage 12
Boehringer Ingelheim GmbH, History 13
Boehringer Ingelheim GmbH, Other Locations 25
Boehringer Ingelheim GmbH, Subsidiaries 25
Boehringer Ingelheim GmbH, Key Competitors 32
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 34
Boehringer Ingelheim GmbH, Recent Deals Summary 35
List of Figures
Boehringer Ingelheim GmbH, Pipeline Products by Therapy Area 11
Boehringer Ingelheim GmbH, Pipeline Products by Development Phase 12
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 33
Boehringer Ingelheim GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 34
